ESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate Cancer

Andrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.